The alarming rate of cancer pervasiveness around the world has caused the spike in demand for gene therapy treatment.
PODs can be utilized in a multitude of applications including: monoclonal antibodies, vaccine or recombinant proteins, personalized medicines, cell and gene therapy and even laboratory use. The utilization of single-use processing equipment within the POD creates the most flexible production platform available. PODs can either be dedicated to a process step or employed as a small volume total process containment solution, involving either glove boxes or isolators within the POD.
PODs can be utilized in a multitude of applications including: monoclonal antibodies, vaccine or recombinant proteins, personalized medicines, cell and gene therapy and even laboratory use. The utilization of single-use processing equipment within the POD creates the most flexible production platform available.
Cell and Gene Therapies have demonstrated real promise as they move into the clinical trial phase for a variety of life changing and deadly diseases. The results of these studies and their potential impact to patients, their loved ones and the industry as a whole are almost incalculable, which makes securing the supply chain mission critical — though not easily accomplished. What makes World Courier so essential for Cell and Gene Therapy logistics is our understanding and our ability to address these critical issues.
G-CON first offered its miniPOD CT product line to serve the cell therapy industry. The CT line provided PODs with unidirectional flow and corridor system included within the 9’ and 12’ wide configurations.
Althea’s focused expertise and capabilities in current Good Manufacturing Practices (cGMP) production of microbial-based biotherapeutics make us one of the industry’s leaders in microbial fermentation. We offer a broad range of microbial-based cGMP biologics manufacturing services to biopharmaceutical companies worldwide. Althea is a recognized leader in plasmid DNA manufacturing for vaccines and gene therapy products. Althea has demonstrated experience in developing and manufacturing nearly 300 cGMP lots of bulk drug substance and has an impeccable regulatory track record. Our comprehensive, validated equipment has been utilized to fulfill numerous drug substance projects for preclinical and clinical supply. For additional information about Althea’s drug substance manufacturing services including contract cGMP microbial fermentation and biologics manufacturing, please contact us.
PCI provides pharmaceutical service solutions for a range of therapies including gene therapies, somatic cell therapies (stem cells) and tissue engineered products also known as Advanced Therapeutic Medicinal Products (ATMPs).
|
|
|
|
|
|
|
|
|